Keyphrases
Retinal pigment Epithelium
100%
Intravitreal Ranibizumab
100%
Retinal pigment Epithelial Tear
100%
Bevacizumab
85%
ETDRS
42%
Intravitreal Injection
28%
Serous
28%
Intravitreal
28%
Anti-VEGF Therapy
28%
Neovascular AMD
28%
Subfoveal
28%
Standard of Care
14%
Efficiency Gain
14%
Retina
14%
Follow-up Examination
14%
Tears
14%
Safety Profile
14%
Systemic Side Effects
14%
Therapeutic Efficiency
14%
Good Safety
14%
Measurement Evaluation
14%
Fluorescein Angiography
14%
Vision Loss
14%
Retinal Thickness
14%
VEGF Inhibitors
14%
Biomicroscopy
14%
Associated Gain
14%
Best-corrected Visual Acuity
14%
Intraocular Pressure Measurement
14%
Fundus Photography
14%
Serous Detachment
14%
Intravitreal anti-VEGF
14%
Medicine and Dentistry
Retinal Pigment Epithelium
100%
Intravitreal Administration
100%
Retina Tear
100%
Bevacizumab
100%
Vasculotropin
42%
Adverse Event
14%
Fluorescein Angiography
14%
Ultrasound Biomicroscopy
14%
Best Corrected Visual Acuity
14%
Fundus Photography
14%
Vasculotropin Inhibitor
14%
Intraocular Pressure
14%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Visual Pigment
100%
Retina Tear
100%
Intravitreal Administration
100%
Vasculotropin
42%
Vasculotropin Inhibitor
14%
Adverse Event
14%
Fluorescein
14%